Could a cheaper copy of ocrevus work just as well for MS?

NCT ID NCT06847724

Ongoing Disease control Sponsor: Sandoz Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether CYB704, a proposed biosimilar to the MS drug Ocrevus, works the same way in the body. About 183 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare drug levels, MRI scans, and side effects to see if the biosimilar is a viable alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ocrelizumab (proposed biosimilar CYB704)
What this could lead to: If successful, CYB704 could offer a more affordable treatment option for relapsing multiple sclerosis, potentially increasing access to care.
What could go wrong: This is a biosimilar study, not a new drug. Even if CYB704 matches Ocrevus in the body, long-term safety and effectiveness still need confirmation. As with Ocrevus, risks include infusion reactions and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Locations

Sandoz Investigational Site

Maitland, Florida, 32751, United States
Sandoz Investigational Site

Ormond Beach, Florida, 32174, United States
Sandoz Investigational Site

Banja Luka, Bosnia and Herzegovina
Sandoz Investigational Site

Bihać, Bosnia and Herzegovina
Sandoz Investigational Site

Sarajevo, Bosnia and Herzegovina
Sandoz Investigational Site

Pleven, Bulgaria
Sandoz Investigational Site

Plovdiv, Bulgaria
Sandoz Investigational Site

Sofia, Bulgaria
Sandoz Investigational Site

Varaždin, Croatia
Sandoz Investigational Site

Zagreb, Croatia
Sandoz Investigational Site

Rustavi, Georgia
Sandoz Investigational Site

Tbilisi, Georgia
Sandoz Investigational Site

Shtip, North Macedonia
Sandoz Investigational Site

Skopje, North Macedonia
Sandoz Investigational Site

Bydgoszcz, Poland
Sandoz Investigational Site

Katowice, Poland
Sandoz Investigational Site

Lodz, Poland
Sandoz Investigational Site

Lublin, Poland
Sandoz Investigational Site

Nowa Sól, Poland
Sandoz Investigational Site

Poznan, Poland
Sandoz Investigational Site

Szczecin, Poland
Sandoz Investigational Site

Warsaw, Poland
Sandoz Investigational Site

Zabrze, Poland
Sandoz Investigational Site

Belgrade, Serbia
Sandoz Investigational Site

Niš, Serbia
Sandoz Investigational Site 2

Sarajevo, Bosnia and Herzegovina
Sandoz Investigational Site 2

Plovdiv, Bulgaria
Sandoz Investigational Site 2

Sofia, Bulgaria
Sandoz Investigational Site 2

Tbilisi, Georgia
Sandoz Investigational Site 2

Katowice, Poland
Sandoz Investigational Site 2

Lublin, Poland
Sandoz Investigational Site 2

Poznan, Poland
Sandoz Investigational Site 3

Sofia, Bulgaria
Sandoz Investigational Site 3

Tbilisi, Georgia
Sandoz Investigational Site 4

Sofia, Bulgaria
Sandoz Investigational Site 4

Tbilisi, Georgia
Sandoz Investigational Site 5

Sofia, Bulgaria
Sandoz Investigational Site 5

Tbilisi, Georgia
Sandoz Investigational Site 6

Tbilisi, Georgia
Sandoz Investigational Site 7

Tbilisi, Georgia
Sandoz Investigational Site 8

Tbilisi, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.